Show simple item record

Evaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.

dc.contributor.authorKhoja, Leila
dc.contributor.authorKumaran, Gireesh C
dc.contributor.authorZee, Ying-Kiat
dc.contributor.authorMurukesh, Nishanth
dc.contributor.authorSwindell, Ric
dc.contributor.authorSaunders, Mark P
dc.contributor.authorClamp, Andrew R
dc.contributor.authorValle, Juan W
dc.contributor.authorWilson, Gregory
dc.contributor.authorJayson, Gordon C
dc.contributor.authorHasan, Jurjees
dc.date.accessioned2013-12-20T10:10:54Z
dc.date.available2013-12-20T10:10:54Z
dc.date.issued2013-10-22
dc.identifier.citationEvaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer. 2013: J Clin Gastroenterolen
dc.identifier.issn1539-2031
dc.identifier.pmid24153157
dc.identifier.doi10.1097/MCG.0b013e3182a8804c
dc.identifier.urihttp://hdl.handle.net/10541/308803
dc.description.abstractThe vascular endothelial growth factor pathway is strongly implicated in cancer-related angiogenesis. Antiangiogenic agents such as bevacizumab commonly cause hypertension (HTN) and proteinuria (PTN), which may be biomarkers of response and clinical outcome.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical gastroenterologyen
dc.titleEvaluation of hypertension and proteinuria as markers of efficacy in antiangiogenic therapy for metastatic colorectal cancer.en
dc.typeArticleen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchester, UK.en
dc.identifier.journalJournal of Clinical Gastroenterologyen
html.description.abstractThe vascular endothelial growth factor pathway is strongly implicated in cancer-related angiogenesis. Antiangiogenic agents such as bevacizumab commonly cause hypertension (HTN) and proteinuria (PTN), which may be biomarkers of response and clinical outcome.


This item appears in the following Collection(s)

Show simple item record